Markus Bluemel
Papers
1
Total Citations
47
H-Index
1
About
Markus Bluemel is a leading figure in biopharmaceutical formulation development, with a specialized focus on the stabilization and high-throughput screening of therapeutic antibodies. His work bridges the critical gap between early-stage discovery and commercial manufacturing, pioneering the integration of robotic automation and high-throughput laboratory (HTL) systems to accelerate formulation design. His most-cited paper, "Formulation Development of Antibodies Using Robotic System and High-Throughput Laboratory (HTL)" (2009, 47 citations), stands as a seminal contribution, demonstrating how miniaturized, automated workflows can rapidly identify optimal buffer and excipient conditions for monoclonal antibodies. This approach dramatically reduces development timelines and material consumption, enabling more robust and cost-effective drug product processes. Bluemel’s contributions have been instrumental in advancing the practical application of high-throughput analytics in the pharmaceutical industry, influencing how biologics are stabilized and delivered. His work continues to inform best practices for formulation scientists, underscoring the power of automation in solving complex stability challenges and ensuring the reliable performance of life-saving antibody therapies.
Research Focus
Key Achievements
Top Papers
- 1